Sugi Predict

Sugi Predict / Compounds / SCHEMBL23344996

SCHEMBL23344996

SCHEMBL23344996

CC(=O)N1CCC(F)(C(C)(C)C)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 3/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ EPHX2 P34913 2/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ USP2 O75604 4/20 0.39
▸ CYP2C19 P33261 3/20 0.38
▸ ALDH1A1 P00352 3/20 0.38
▸ MEN1 O00255 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ MAPK1 P28482 2/20 0.38
▸ HPGD P15428 2/20 0.37
▸ CYP2C9 P11712 4/20 0.37
▸ TSHR P16473 1/20 0.37
▸ CYP2D6 P10635 2/20 0.36
▸ CYP3A4 P08684 2/20 0.36
▸ ALOX12 P18054 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ HSP90AA1 P07900 1/20 0.35
▸ HSP90AB1 P08238 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23075806 0.78 SMN1; SMN2 (0.43) CYP1A2TDP1EPHX2SMN1; SMN2KDM4E
SCHEMBL23309174 0.78 CYP1A2 (0.44) CYP1A2TDP1EPHX2SMN1; SMN2KDM4E
SCHEMBL3434463 0.78 EPHX2 (0.55) CYP1A2TDP1EPHX2SMN1; SMN2KDM4E
SCHEMBL18125616 0.77 USP2 (0.51) EPHX2SMN1; SMN2USP2MEN1KMT2A
SCHEMBL23309207 0.77 CYP1A2 (0.43) CYP1A2TDP1EPHX2SMN1; SMN2KDM4E
SCHEMBL23077821 0.77 CYP1A2 (0.43) CYP1A2TDP1EPHX2SMN1; SMN2KDM4E
SCHEMBL8383076 0.76 CYP1A2 (0.46) CYP1A2TDP1EPHX2SMN1; SMN2KDM4E
SCHEMBL26812142 0.76 CYP1A2 (0.46) CYP1A2TDP1EPHX2SMN1; SMN2KDM4E
SCHEMBL23345014 0.75 CYP1A2 (0.41) CYP1A2TDP1EPHX2SMN1; SMN2KDM4E
SCHEMBL12437095 0.74 CYP1A2 (0.44) CYP1A2TDP1EPHX2SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230183217-A1 INHIBITORS OF LRRK2 KINASE HALIA THERAPEUTICS INC (US) 2023-06-15 — — US disclosed
US-20230183217-A1 INHIBITORS OF LRRK2 KINASE HALIA THERAPEUTICS INC (US) 2023-06-15 — — US disclosed
US-11578061-B2 Inhibitors of LRRK2 kinase Halia Therapeutics, Inc. (US) 2023-02-14 — — US disclosed
US-11168102-B1 Bicyclic heteroaryl compounds and uses thereof Revolution Medicines, Inc. (US) 2021-11-09 — — US disclosed
US-20210139517-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF Revolution Medicines, Inc. 2021-05-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183217-A1 INHIBITORS OF LRRK2 KINASE LRRK2, SNCA, PRKAR2B CYP1A2 4088/4885TDP1 448/4885EPHX2 4094/4885
US-11168102-B1 Bicyclic heteroaryl compounds and uses thereof SOS1, SOST, SOS2 CYP1A2 1997/4885TDP1 2014/4885EPHX2 2126/4885
US-11578061-B2 Inhibitors of LRRK2 kinase LRRK2, SNCA, PRKAR2B CYP1A2 4088/4885TDP1 448/4885EPHX2 4094/4885
US-20210139517-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF SOST, SOS1, SOS2 CYP1A2 2086/4885TDP1 1675/4885EPHX2 1872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.